Drug Type Small molecule drug |
Synonyms ONO-7475, ONO7475 |
Target |
Action inhibitors |
Mechanism AXL inhibitors(AXL receptor tyrosine kinase inhibitors), MerTK inhibitors(Tyrosine-protein kinase Mer inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC32H26N4O6 |
InChIKeyWHMMKPWGWNYYFE-UHFFFAOYSA-N |
CAS Registry1646839-59-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
acute leukemia | Phase 2 | United States | 26 Jun 2017 | |
Myelodysplastic Syndromes | Phase 2 | United States | 26 Jun 2017 | |
Acute Myeloid Leukemia | Phase 2 | United States | - | |
Metastatic Pancreatic Cancer | Phase 1 | Japan | 06 Dec 2023 | |
EGFR mutation Solid Tumors | Phase 1 | Japan | 06 Aug 2021 | |
EGFR positive non-small cell lung cancer | Phase 1 | Japan | 06 Aug 2021 | |
metastatic non-small cell lung cancer | Phase 1 | Japan | 06 Aug 2021 | |
Non-small cell lung cancer stage IIIB | Phase 1 | Japan | 06 Aug 2021 | |
Recurrent Non-Small Cell Lung Cancer | Phase 1 | Japan | 06 Aug 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | Japan | 17 Oct 2018 |
Phase 1 | 24 | jpvskdccmn(mnnybxzegp) = activation of T cell function and an increase in T cell number, an increase in inflammatory (M1) macrophages / immunosuppressive (M2) macrophages ratio, and suppression of epithelial-to-mesenchymal transition were observed after treatment. ahwwlwrouy (busrwqgogj ) View more | Positive | 08 Apr 2024 | |||
Phase 1 | 42 | ixvtlzinck(pnkidoyjiz) = ijqqnpmiaa pehtfcwohs (hfjcqmpree ) | - | 01 Jul 2018 |